Results
929
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
929 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
QNST | US$23.71 | 0.6% | 91.1% | US$1.3b | US$29.00 | PS1.7x | E105.0% | n/a | Media | ||
3231 | NT$99.00 | -10.0% | -20.5% | NT$285.9b | NT$146.67 | PE18.5x | E27.7% | 2.6% | Tech | ||
3526 | NT$265.00 | 0.2% | 38.4% | NT$16.7b | NT$350.00 | PE18.4x | E25.1% | 4.3% | Tech | ||
MOTO | €2.72 | -1.6% | -12.3% | €79.5m | €3.80 | PE6.8x | E11.5% | 4.5% | Retail | ||
ERIC B | SEK 83.22 | -2.2% | 47.3% | SEK 278.4b | SEK 84.42 | PE13867.2x | E46.6% | 3.4% | Tech | ||
FACE | €2.23 | 4.2% | 6.2% | €50.2m | €2.00 | PS1.6x | E72.6% | n/a | Software | ||
BRKL | US$12.06 | -0.2% | 18.8% | US$1.1b | US$14.94 | PB0.9x | E94.3% | 4.5% | Banks | ||
KXS | CA$171.05 | -2.0% | 5.9% | CA$4.7b | CA$198.62 | PE162.2x | E42.9% | n/a | Software | ||
EFX | US$267.52 | -2.7% | 9.3% | US$34.1b | US$305.32 | PE59x | E25.1% | 0.6% | Commercial Services | ||
S32 | AU$3.38 | 0.3% | 7.6% | AU$15.2b | AU$3.81 | PS1.7x | E52.0% | 1.7% | Materials | ||
2762 | NT$90.30 | -2.6% | -6.9% | NT$9.9b | NT$122.33 | PE25.1x | E45.7% | 2.5% | Consumer Services | ||
BRCK | UK£0.56 | -2.5% | -17.0% | UK£182.3m | UK£0.97 | PE21.5x | E46.5% | 6.0% | Capital Goods | ||
688046 | CN¥13.06 | 0% | 8.8% | CN¥5.3b | CN¥14.00 | PE38.3x | E24.2% | 0.5% | Pharmaceuticals & Biotech | ||
TOY | CA$30.63 | -3.8% | -13.4% | CA$3.2b | CA$43.47 | PE70.2x | E22.8% | 1.6% | Consumer Durables | ||
2268 | HK$28.45 | 2.0% | 63.9% | HK$34.1b | HK$36.43 | PE53.4x | E26.9% | n/a | Pharmaceuticals & Biotech | ||
SVIK | SEK 124.80 | 3.3% | -1.7% | SEK 1.0b | n/a | PE34.9x | E45.6% | 1.6% | Commercial Services | ||
TFBANK | SEK 379.00 | 1.6% | 125.3% | SEK 8.0b | SEK 456.67 | PB2.9x | E17.4% | n/a | Banks | ||
GROY | US$1.33 | 9.9% | 0.8% | US$223.5m | US$3.02 | PS29x | E171.6% | 0% | Materials | ||
VRRM | US$26.19 | -2.5% | 18.5% | US$4.3b | US$29.17 | PE42.7x | E23.5% | n/a | Commercial Services | ||
300702 | CN¥17.32 | 0% | 13.5% | CN¥6.0b | CN¥22.42 | PE136.4x | E71.4% | 0.3% | Pharmaceuticals & Biotech | ||
MSAB B | SEK 57.80 | 7.0% | -1.9% | SEK 1.1b | SEK 79.00 | PE28.5x | E21.0% | 2.6% | Software | ||
BUFAB | SEK 468.20 | 0.2% | 27.9% | SEK 17.5b | SEK 467.50 | PE34.7x | E20.8% | 1.1% | Capital Goods | ||
PWG | €0.58 | 1.0% | -42.2% | €28.9m | €0.66 | PS0.5x | E118.8% | n/a | Capital Goods | ||
VCT | UK£9.93 | 0.4% | -27.6% | UK£849.6m | UK£12.55 | PE50.2x | E29.4% | 6.0% | Materials |